Compare IQIYI Inc - ADR (IQ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? IQIYI Inc - ADR trades at $0.94 (market cap $918.03M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: IQIYI Inc - ADR and Maravai LifeSciences Holdings Inc. Class A Common Stock are close in size by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IQ | MRVI | |
|---|---|---|
Market Cap | $918.03M | $977.37M |
Volume | 10,354,180 | 2,742,564 |
Sector | Media | Health |
52-Week High | $2.35 | $9.00 |
52-Week Low | $0.86 | $2.83 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $2.41B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $0.99, down 2.78% today, with a neutral technical signal. The company reported a net loss of $206 million in 2025 despite beating EPS estimates in recent quarters. Revenue has declined from $31.9B in 2023 to $27.3B in 2025. Analyst sentiment is mixed with a 50% buy rating. Recent news highlights AI-driven content initiatives, including the successful 'The Ferry Man' series.
The outlook is cautious; while AI innovation offers growth potential, persistent revenue declines and negative margins pose risks. The stock's low P/S and P/B ratios suggest undervaluation, but profitability challenges and high debt levels require careful monitoring. Upside depends on successful execution of AI content strategy and return to revenue growth.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
